A Phase 2/3 interventional study of Tranexamic acid in Postoperative Blood Loss, sponsored by Ascension Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-16.
Sponsored by Ascension Health · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing Tranexamic Acid in Postoperative Hemorrhage — 5 open to participants now, 5 under way, 1 of them phase 3. Tranexamic Acid · Postoperative Hemorrhage.
Among the 25 studies testing Tranexamic Acid in Postoperative Hemorrhage, this one is the 7th largest by planned enrollment, is one of 3 that started in 2021, is one of 2 in phase 2/3, and was the 17th registered.
135 studies on the registry are indexed under Postoperative Hemorrhage; 31 are open to participants now.
Browse Postoperative Hemorrhage studies →5 of the 25 studies testing Tranexamic Acid in Postoperative Hemorrhage are open now, in 4 countries. Recruiting first, the newest first:
St. Mary's Research Center, Canada · Sites in Canada
Ages 18+ · Healthy volunteers
Vanderbilt University Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
Clinique Saint-Luc · Sites in Belgium
Ages 18+
Ramathibodi Hospital · Sites in Thailand
Ages 18–50
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 17 Postoperative Hemorrhage studies recruiting now, 11 (65%) set no upper age limit and 4 (24%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 5 · Phase 4 10
First in 2008; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 170 is above the median of 100 across 102 interventional studies indexed under Postoperative Hemorrhage.
Median enrollment 116 across the 25 interventional studies. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 25 have an industry lead sponsor. The 10 most frequent:
Ascension Health is the lead sponsor of 21 studies on the registry; 3 are open to participants now.
Ascension Health has 1 study filed under Postoperative Hemorrhage — fewer than ten, so there is no comparison to draw.
1 of the studies testing Tranexamic Acid in Postoperative Hemorrhage that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06208267St. Mary's Research Center, CanadaTranexamic Acid Use on Pain, Mobility and Bleeding Following Total Hip and Total Knee Arthroplasty | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing Tranexamic Acid in Postoperative Hemorrhage, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group receives 1 G of TXA as soon as possible after a diagnosis of an acute hip fracture if the patient meets inclusion and exclusion criteria. The group will also receive 2 grams of TXA total intraoperatively.
Drug: Tranexamic acid
This group will only receive the intraoperative TXA.
Drug: Tranexamic acid
TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
Also known as: Lysteda
Postoperative Blood Transfusion
Patient receives a blood transfusion during their postoperative stay in the hospital
Time frame: Up to two weeks
Overall Blood Loss
Calculate the difference in postoperative blood loss between groups
Time frame: Up to two weeks
Length of hospital stay
Overall length of hospital stay
Time frame: Up to two weeks
Postoperative Pain
Difference in overall pain scores between groups
Time frame: Up to two weeks
Wound complications
Acute wound complications documented after surgical intervention
Time frame: Up to two weeks
Acute DVT/PE
Documented deep venous thrombosis or pulmonary embolism
Time frame: Up to two weeks
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2021 (actual). Primary completion is estimated for Jul 2022, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
Ascension Health